Effect of paraoxonase 1 gene polymorphisms on clinical course of Henoch-Schönlein purpura

Journal of Nephrology

Volumn 22, Issue 6, 2009, Pages 726-732

  Yilmaz, Alev ^a   Emre, Sevinc ^b   Agachan, Bedia ^c   Bilge, Ilmay ^b   Yilmaz, Hulya ^c   Ergen, Arzu ^c   Isbir, Turgay ^c   Sirin, Aydan ^b  

^a Istanbul Bakirkoy Maternity and Children Diseases Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Inst for Exp Medical Research   (Turkey)

Author keywords

Children; Gene; Henoch Sch nlein purpura; Kidney; Oxidative stress; Paraoxonase1; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADOLESCENT; ANAPHYLACTOID PURPURA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; OXIDATIVE STRESS; PROTEINURIA; RISK FACTOR; TURKEY (REPUBLIC);

ADOLESCENT; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC TESTING; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; NEPHRITIS; ODDS RATIO; OPEN READING FRAMES; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEINURIA; PURPURA, SCHOENLEIN-HENOCH; RISK ASSESSMENT; RISK FACTORS; TURKEY;

EID: 72149098405     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003;54:371-392.
2. Frishberg Y, Toledano H, Becker-Cohen R, Feigin E, Halle D. Genetic polymorphism in paraoxonase is a risk factor for childhood focal segmental glomerulosclerosis. Am J Kidney Dis. 2000;36:1253-1261.
3. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38:153-163.
4. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004;107:435-447.
5. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis Suppl. 2002;3:49-55.
6. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498-507.
7. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003;81:766-779..
8. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab. 2002;28:297-304.
9. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct. 2004;22:163-168.
10. Wang H, Deng H, Liu W. The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus. Zhonghua Nei Ke Za Zhi. 2002;41:179-182.
11. Yavuz DG, Yuksel M, Deyneli O, Ozen Y, Aydin H, Akalin S. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients. Clin Endocrinol (Oxf). 2004;61:515-521.
12. Ak G, Ozgonul M, Sozmen EY, Aslan SL, Sozmen B. Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol. Mar-2002 Apr;15(2):144-149.
13. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813-818.
14. Schiavon R, Battaglia P, De Fanti E, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39-44.
15. Delgado Alves J, Ames PR, Donohue S, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2002;46:2686-2694.
16. Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. Br J Ophthalmol. 2004;88:1256-1258.
17. Tanimoto N, Kumon Y, Suehiro T, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 2003;72:2877-2885.
18. Granér M, James RW, Kahri J, Nieminen MS, Syvänne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006;47:2429-2435.
19. Ueno T, Shimazaki E, Matsumoto T, et al. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Med Sci Monit. 2003;9:CR208-CR212.
20. Chen Q, Reis SE, Kamerer CM, et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet. 2003;72:13-22.
21. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke. 2002;33:1459-1464.
22. Schmidt H, Schmidt R, Niederkorn K, et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke. 1998;29:2043-2048.
23. Fortunato G, Rubba P, Panico S, et al. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis. 2003;167:141-148.
24. Malin R, Jarvinen O, Sisto T, Koivula T, Lehtimaki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis. 2001;157:301-307.
25. Biyikli NK, Alpay H, Yildiz N, et al. Paraoxonase 1 192 and 55 polymorphism in nephritic children. Pediatr Nephrol. 2006;21:649-654.
26. Ece A, Kelekçi S, Kocamaz H, et al. Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch-Schönlein purpura. Clin Rheumatol. 2008;27:163-169.
27. Coppo R, Amore A. Henoch-Schönlein purpura. In: Avner ED, Harmon WE, Niaudet P, eds. Pediatric nephrology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:851-863.
28. Webb NJA, Brogan PA, Baildam EM. Renal manifestations of systemic disorders. In: Webb NJ, Postlethwaite R, eds. Clinical paediatric nephrology. 3rd ed. New York: Oxford University Press; 2003:381-403.
29. Rieu P, Noel LH. Henoch-Schonlein nephritis in children and adults: morphological features and clinicopathological correlations. Ann Med Interne (Paris). 1999;150:151-159.
30. Miller ML, Pachman LM. Vasculitis syndromes. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th ed. Philadelphia, PA: Saunders; 2004:826-831.
31. Sundel R, Szer I. Vasculitis in childhood: rheumatic disease clinics of North America Pediatric Rheumatology. 2002;3:625-654.
32. Rai A, Nast C, Adler S. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol. 1999;10:2637-2644.
33. Wyatt RJ, Novak J, Gaber LW, Lau KK. Immunglobulin A nephropathy and Henoch-Schönlein Purpura Nephritis. In: Kher KK, Schnaper HW, Makker SP, eds. Clinical Pediatric Nephrology. Second edition. London: Informa UK Ltd., 2007: 213-221
34. Erdogan O, Oner A, Aydin A, Isimer A, Demircin G, Bulbul M. Effect of vitamin E treatment on the oxidative damage occurring in Henoch-Schonlein purpura. Acta Paediatr. 2003;92:546-550.
35. Demircin G, Oner A, Unver Y, Bulbul M, Erdogan O. Erythrocyte superoxide dismutase activity and plasma malondialdehyde levels in children with Henoch Schonlein purpura. Acta Paediatr. 1998;87:848-852.
36. Buyan N, Erbas D, Akkok N, Oz E, Biberoglu G, Hasanoglu E. Role of free oxygen radicals and prostanoids in the pathogenesis of Henoch-Schonlein Purpura. Prostaglandins Leukot Essent Fatty Acids. 1998;59:181-184.
37. Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990;33:1114-1121.
38. White RHR, Yoshikawa N, Feehally J. IgA nephropathy and Henoch-Schönlein nephritis. In: Barratt T, Avner ED, Harmon WE, eds. Pediatric nephrology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:691-706.
39. Miller SA, Dykes DD, Polesky HS. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
40. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
41. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191 for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
42. Bilge I, Sirin A, Agachan B, et al. Is paraoxonase 192 gene polymorphism a risk factor for membranoproliferative glomerulonephritis in children? Cell Biochem Funct. 2007;25:159-165.
43. Kovacs TJ, Harris S, Vas TK, et al. Paraoxonase gene polymorphisms and the progression of IgA nephropathy. J Nephrol. 2006;19:732-738.
44. Nelson C, Glare E, Wilson A, Cotton R, Packham D, Becker G, Best J, Jenkins A. Paraoxonase 1 genotype and phenotype are associated with renal function and vascular and systemic inflammation in IgA nephropathy. Nephrol. Dial. Transplant., 2003;18:847-898.
45. Amoli MM, Calvino MC, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA. Interleukin 1beta gene polymorphism association with severe renal manifestations and renal sequelae in Henoch-Schonlein purpura. J Rheumatol. 2004;31:295-298.